"That is huge for glioblastoma patients. It could potentially prevent patients from getting prolonged treatments that are ineffective..."

In a new preclinical study, researchers from The University of Texas MD Anderson Cancer Center developed an antibody therapy called 77A that showed an ability to overcome treatment resistance in blood cancers, such as myeloma and lymphoma, as well as solid tumors.